Stockreport

AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma [Yahoo! Finance]

AbbVie Inc.  (ABBV) 
Last abbvie inc. earnings: 5/1 07:43 am Check Earnings Report
US:NYSE Investor Relations: investors.abbvie.com/investor-overview
PDF patients with relapsed or refractory follicular lymphoma after at least one line of systemic therapy In the Phase 3 EPCORE ® FL-1 trial, EPKINLY + R demonstrated signifi [Read more]